FI113666B - Menetelmiä, joissa käytetään kromosomin 12 spesifisiä katkoskohtia ja/tai neuroninavigaattori 3 -geeniä ihon primaaristen T-solulymfoomien diagnosoimiseksi ja taudin etenemisen seuraamiseksi tai ennustamiseksi, sekä näiden katkoskohtien ja geenien käyttö - Google Patents
Menetelmiä, joissa käytetään kromosomin 12 spesifisiä katkoskohtia ja/tai neuroninavigaattori 3 -geeniä ihon primaaristen T-solulymfoomien diagnosoimiseksi ja taudin etenemisen seuraamiseksi tai ennustamiseksi, sekä näiden katkoskohtien ja geenien käyttö Download PDFInfo
- Publication number
- FI113666B FI113666B FI20021617A FI20021617A FI113666B FI 113666 B FI113666 B FI 113666B FI 20021617 A FI20021617 A FI 20021617A FI 20021617 A FI20021617 A FI 20021617A FI 113666 B FI113666 B FI 113666B
- Authority
- FI
- Finland
- Prior art keywords
- chromosome
- gene
- translocation
- chromosomal
- region
- Prior art date
Links
- 210000000349 chromosome Anatomy 0.000 title claims description 167
- 108090000623 proteins and genes Proteins 0.000 title claims description 85
- 238000000034 method Methods 0.000 title claims description 49
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 30
- 201000010099 disease Diseases 0.000 title claims description 29
- 206010042971 T-cell lymphoma Diseases 0.000 title claims description 26
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 title claims description 15
- 101710145274 Neuron navigator 3 Proteins 0.000 title claims description 11
- 210000004986 primary T-cell Anatomy 0.000 title claims description 5
- 230000005945 translocation Effects 0.000 claims description 91
- 201000005962 mycosis fungoides Diseases 0.000 claims description 82
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims description 51
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 51
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims description 49
- 230000002759 chromosomal effect Effects 0.000 claims description 43
- 239000000523 sample Substances 0.000 claims description 34
- 102000004169 proteins and genes Human genes 0.000 claims description 27
- 239000000463 material Substances 0.000 claims description 24
- 101100348015 Homo sapiens NAV3 gene Proteins 0.000 claims description 21
- 101150026704 NAV3 gene Proteins 0.000 claims description 21
- 238000012217 deletion Methods 0.000 claims description 21
- 230000037430 deletion Effects 0.000 claims description 21
- 208000009359 Sezary Syndrome Diseases 0.000 claims description 20
- 208000021388 Sezary disease Diseases 0.000 claims description 20
- 238000004458 analytical method Methods 0.000 claims description 19
- 239000012634 fragment Substances 0.000 claims description 19
- 102100030464 Neuron navigator 3 Human genes 0.000 claims description 18
- 239000012472 biological sample Substances 0.000 claims description 15
- 208000037088 Chromosome Breakage Diseases 0.000 claims description 10
- 238000003745 diagnosis Methods 0.000 claims description 10
- 238000007901 in situ hybridization Methods 0.000 claims description 10
- 238000012544 monitoring process Methods 0.000 claims description 9
- 230000001537 neural effect Effects 0.000 claims description 9
- 239000003153 chemical reaction reagent Substances 0.000 claims description 8
- 238000002405 diagnostic procedure Methods 0.000 claims description 8
- 208000034951 Genetic Translocation Diseases 0.000 claims description 7
- 206010025323 Lymphomas Diseases 0.000 claims description 7
- 230000002559 cytogenic effect Effects 0.000 claims description 7
- 206010061818 Disease progression Diseases 0.000 claims description 5
- 230000005750 disease progression Effects 0.000 claims description 5
- 239000003298 DNA probe Substances 0.000 claims description 4
- 238000009396 hybridization Methods 0.000 claims description 4
- 238000010186 staining Methods 0.000 claims description 4
- 238000012360 testing method Methods 0.000 claims description 4
- 239000000872 buffer Substances 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 210000000245 forearm Anatomy 0.000 claims description 3
- 238000011002 quantification Methods 0.000 claims description 3
- 230000003595 spectral effect Effects 0.000 claims description 3
- 238000001228 spectrum Methods 0.000 claims description 3
- 238000012800 visualization Methods 0.000 claims description 3
- 230000001413 cellular effect Effects 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- 238000011065 in-situ storage Methods 0.000 claims description 2
- 239000003973 paint Substances 0.000 claims description 2
- 101150072531 10 gene Proteins 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000024191 minimally invasive lung adenocarcinoma Diseases 0.000 description 64
- 210000004027 cell Anatomy 0.000 description 23
- 238000002509 fluorescent in situ hybridization Methods 0.000 description 20
- 210000002230 centromere Anatomy 0.000 description 19
- 210000003491 skin Anatomy 0.000 description 19
- 230000002159 abnormal effect Effects 0.000 description 17
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 16
- 230000006870 function Effects 0.000 description 14
- 206010028980 Neoplasm Diseases 0.000 description 13
- 201000011510 cancer Diseases 0.000 description 12
- 238000001514 detection method Methods 0.000 description 12
- 230000003211 malignant effect Effects 0.000 description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
- 101000582005 Homo sapiens Neuron navigator 3 Proteins 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- 230000014616 translation Effects 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical class CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 241000764238 Isis Species 0.000 description 4
- 229960002685 biotin Drugs 0.000 description 4
- 235000020958 biotin Nutrition 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 238000013399 early diagnosis Methods 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 241000283707 Capra Species 0.000 description 3
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 108091008874 T cell receptors Proteins 0.000 description 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000004590 computer program Methods 0.000 description 3
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 3
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 230000036210 malignancy Effects 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 230000031864 metaphase Effects 0.000 description 3
- 239000013610 patient sample Substances 0.000 description 3
- 230000000306 recurrent effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 101150090724 3 gene Proteins 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 102000005369 Aldehyde Dehydrogenase Human genes 0.000 description 2
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 description 2
- 208000003950 B-cell lymphoma Diseases 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 101100316120 Caenorhabditis elegans unc-53 gene Proteins 0.000 description 2
- 208000031404 Chromosome Aberrations Diseases 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- 101710176246 High mobility group protein Proteins 0.000 description 2
- WGZDBVOTUVNQFP-UHFFFAOYSA-N N-(1-phthalazinylamino)carbamic acid ethyl ester Chemical compound C1=CC=C2C(NNC(=O)OCC)=NN=CC2=C1 WGZDBVOTUVNQFP-UHFFFAOYSA-N 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- 239000000074 antisense oligonucleotide Substances 0.000 description 2
- 238000012230 antisense oligonucleotides Methods 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 231100000005 chromosome aberration Toxicity 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 230000001589 lymphoproliferative effect Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 229930002330 retinoic acid Natural products 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 101150098072 20 gene Proteins 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
- 241000244202 Caenorhabditis Species 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 102000049982 HMGA2 Human genes 0.000 description 1
- 108700039143 HMGA2 Proteins 0.000 description 1
- 102000018802 High Mobility Group Proteins Human genes 0.000 description 1
- 102100029009 High mobility group protein HMG-I/HMG-Y Human genes 0.000 description 1
- 102100028999 High mobility group protein HMGI-C Human genes 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101000986380 Homo sapiens High mobility group protein HMG-I/HMG-Y Proteins 0.000 description 1
- 101000986379 Homo sapiens High mobility group protein HMGI-C Proteins 0.000 description 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- 101000610557 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp31 Proteins 0.000 description 1
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 102000002151 Microfilament Proteins Human genes 0.000 description 1
- 108010040897 Microfilament Proteins Proteins 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 108010047620 Phytohemagglutinins Proteins 0.000 description 1
- 229920000037 Polyproline Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 208000028561 Primary cutaneous T-cell lymphoma Diseases 0.000 description 1
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 101001109965 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L7-A Proteins 0.000 description 1
- 101001109960 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L7-B Proteins 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
- 102100040118 U4/U6 small nuclear ribonucleoprotein Prp31 Human genes 0.000 description 1
- 206010046798 Uterine leiomyoma Diseases 0.000 description 1
- 108700025690 abl Genes Proteins 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000000701 chemical imaging Methods 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 208000024386 fungal infectious disease Diseases 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 238000012333 histopathological diagnosis Methods 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 230000002895 hyperchromatic effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- NIQQIJXGUZVEBB-UHFFFAOYSA-N methanol;propan-2-one Chemical compound OC.CC(C)=O NIQQIJXGUZVEBB-UHFFFAOYSA-N 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 206010033898 parapsoriasis Diseases 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 210000004214 philadelphia chromosome Anatomy 0.000 description 1
- 230000001885 phytohemagglutinin Effects 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 108010026466 polyproline Proteins 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108700001569 prostate apoptosis response-4 Proteins 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000017105 transposition Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 201000007954 uterine fibroid Diseases 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Priority Applications (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20021617A FI113666B (fi) | 2002-01-24 | 2002-09-10 | Menetelmiä, joissa käytetään kromosomin 12 spesifisiä katkoskohtia ja/tai neuroninavigaattori 3 -geeniä ihon primaaristen T-solulymfoomien diagnosoimiseksi ja taudin etenemisen seuraamiseksi tai ennustamiseksi, sekä näiden katkoskohtien ja geenien käyttö |
| CA 2474446 CA2474446A1 (en) | 2002-01-24 | 2003-01-24 | A method for the diagnosis of lymphoproliferative diseases |
| AU2003201630A AU2003201630A1 (en) | 2002-01-24 | 2003-01-24 | A method for the diagnosis of lymphoproliferative diseases |
| PCT/FI2003/000061 WO2003066898A1 (en) | 2002-01-24 | 2003-01-24 | A method for the diagnosis of lymphoproliferative diseases |
| EP03700329A EP1476567A1 (en) | 2002-01-24 | 2003-01-24 | A method for the diagnosis of lymphoproliferative diseases |
| US10/502,638 US7803532B2 (en) | 2002-01-24 | 2003-01-24 | Method for the diagnosis of lymphoproliferative diseases |
| JP2003566246A JP4782378B2 (ja) | 2002-01-24 | 2003-01-24 | リンパ球異常増殖疾患の診断方法 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20020132A FI20020132A7 (fi) | 2002-01-24 | 2002-01-24 | Diagnostisia ja terapeuttisia menetelmiä |
| FI20020132 | 2002-01-24 | ||
| FI20021617 | 2002-09-10 | ||
| FI20021617A FI113666B (fi) | 2002-01-24 | 2002-09-10 | Menetelmiä, joissa käytetään kromosomin 12 spesifisiä katkoskohtia ja/tai neuroninavigaattori 3 -geeniä ihon primaaristen T-solulymfoomien diagnosoimiseksi ja taudin etenemisen seuraamiseksi tai ennustamiseksi, sekä näiden katkoskohtien ja geenien käyttö |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI20021617A0 FI20021617A0 (fi) | 2002-09-10 |
| FI20021617A7 FI20021617A7 (fi) | 2003-07-25 |
| FI113666B true FI113666B (fi) | 2004-05-31 |
Family
ID=26161265
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI20021617A FI113666B (fi) | 2002-01-24 | 2002-09-10 | Menetelmiä, joissa käytetään kromosomin 12 spesifisiä katkoskohtia ja/tai neuroninavigaattori 3 -geeniä ihon primaaristen T-solulymfoomien diagnosoimiseksi ja taudin etenemisen seuraamiseksi tai ennustamiseksi, sekä näiden katkoskohtien ja geenien käyttö |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7803532B2 (enExample) |
| EP (1) | EP1476567A1 (enExample) |
| JP (1) | JP4782378B2 (enExample) |
| AU (1) | AU2003201630A1 (enExample) |
| CA (1) | CA2474446A1 (enExample) |
| FI (1) | FI113666B (enExample) |
| WO (1) | WO2003066898A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008059112A1 (en) * | 2006-11-13 | 2008-05-22 | Dermagene Oy | Methods and uses involving genetic abnormalities at chromosome 12 |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0878552A1 (en) | 1997-05-13 | 1998-11-18 | Erasmus Universiteit Rotterdam | Molecular detection of chromosome aberrations |
| JP2002513587A (ja) | 1998-05-04 | 2002-05-14 | ダコ エー エス | 染色体異常を検出するための方法およびプローブ |
| WO2007071829A2 (en) | 2005-12-22 | 2007-06-28 | Dermagene Oy | Methods and means related to diseases |
| ES2534769T3 (es) | 2007-09-20 | 2015-04-28 | Valipharma | Diagnóstico de linfoma de linfocitos B |
| WO2009126804A2 (en) * | 2008-04-11 | 2009-10-15 | The Regents Of The University Of Colorado, A Body Corporate | Expression of kir in human cancer cells as a biomarker for immuno-escape and cancer metastasis |
| CA2740351A1 (en) * | 2008-10-20 | 2010-04-29 | Pharmatest Services Ltd. | Methods and uses involving genetic aberrations of nav3 and aberrant expression of multiple genes |
| EP4034567A4 (en) * | 2019-09-23 | 2023-07-05 | Neonc Technologies, Inc. | PHARMACEUTICAL COMPOSITIONS WITH POH DERIVATIVES |
| JP7258224B2 (ja) | 2020-03-16 | 2023-04-14 | 株式会社マンダム | Ｔ細胞性リンパ腫の指標の検出方法、及びその利用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6007994A (en) * | 1995-12-22 | 1999-12-28 | Yale University | Multiparametric fluorescence in situ hybridization |
| ES2534769T3 (es) * | 2007-09-20 | 2015-04-28 | Valipharma | Diagnóstico de linfoma de linfocitos B |
-
2002
- 2002-09-10 FI FI20021617A patent/FI113666B/fi not_active IP Right Cessation
-
2003
- 2003-01-24 JP JP2003566246A patent/JP4782378B2/ja not_active Expired - Fee Related
- 2003-01-24 AU AU2003201630A patent/AU2003201630A1/en not_active Abandoned
- 2003-01-24 CA CA 2474446 patent/CA2474446A1/en not_active Abandoned
- 2003-01-24 WO PCT/FI2003/000061 patent/WO2003066898A1/en not_active Ceased
- 2003-01-24 US US10/502,638 patent/US7803532B2/en not_active Expired - Fee Related
- 2003-01-24 EP EP03700329A patent/EP1476567A1/en not_active Withdrawn
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008059112A1 (en) * | 2006-11-13 | 2008-05-22 | Dermagene Oy | Methods and uses involving genetic abnormalities at chromosome 12 |
Also Published As
| Publication number | Publication date |
|---|---|
| US7803532B2 (en) | 2010-09-28 |
| EP1476567A1 (en) | 2004-11-17 |
| US20050221309A1 (en) | 2005-10-06 |
| JP2005518790A (ja) | 2005-06-30 |
| WO2003066898A1 (en) | 2003-08-14 |
| FI20021617A0 (fi) | 2002-09-10 |
| AU2003201630A1 (en) | 2003-09-02 |
| CA2474446A1 (en) | 2003-08-14 |
| FI20021617A7 (fi) | 2003-07-25 |
| JP4782378B2 (ja) | 2011-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Möller et al. | FUS-CREB3L2/L1–positive sarcomas show a specific gene expression profile with upregulation of CD24 and FOXL1 | |
| Le et al. | Dysregulation of the NRG1/ERBB pathway causes a developmental disorder with gastrointestinal dysmotility in humans | |
| EP2761300A2 (en) | Recurrent gene fusions in breast cancer | |
| Sagaert et al. | MALT1 and BCL10 aberrations in MALT lymphomas and their effect on the expression of BCL10 in the tumour cells | |
| JP2011505579A (ja) | 眼圧を変調し、ステロイドの応答者と非応答者とを鑑別するための分子標的 | |
| JP5714327B2 (ja) | 心筋炎のトランスクリプトームのバイオマーカー | |
| FI113666B (fi) | Menetelmiä, joissa käytetään kromosomin 12 spesifisiä katkoskohtia ja/tai neuroninavigaattori 3 -geeniä ihon primaaristen T-solulymfoomien diagnosoimiseksi ja taudin etenemisen seuraamiseksi tai ennustamiseksi, sekä näiden katkoskohtien ja geenien käyttö | |
| Cocchi et al. | CIC rearranged sarcomas: A single institution experience of the potential pitfalls in interpreting CIC FISH results | |
| US20110151443A1 (en) | Marker for gastric cancer | |
| WO2011081421A2 (en) | Complement c9 as markers for the diagnosis of cancer | |
| Cocchi et al. | The utility of FISH analysis in the diagnosis of BCOR-rearranged sarcomas | |
| EP0966531B1 (en) | Tazarotene-induced gene 3 (tig3) | |
| WO2014207170A1 (en) | Methods for monitoring treatment response and relapse in ovarian cancer | |
| JP2800850B2 (ja) | 新生物形成の検出方法 | |
| KR101492024B1 (ko) | 전이성 뇌종양 진단용 마커 | |
| KR101365206B1 (ko) | 심장근육병 진단용 마커 Ｏｒａｉ１ | |
| JP5734947B2 (ja) | 異常型ミトコンドリアｄｎａ、関連融合転写物および翻訳産物、並びにそのハイブリダイゼーションプローブ | |
| US6255049B1 (en) | Detection of metastatic cancer cells using PCTA-1 | |
| EP1959022A1 (en) | Detection of uterine leiomyosarcoma using lmp2 | |
| WO2021172315A1 (ja) | Ｌａｍｃ２－ｎｒ６ａ１スプライシングバリアント及びその翻訳産物 | |
| KR101727750B1 (ko) | 단맛 수용체 유전자를 함유하는 허혈질환 진단용 조성물 | |
| CN113373229B (zh) | 胃癌相关生物标志物及其应用 | |
| Hahn et al. | The role of cytogenetics and molecular genetics in soft tissue tumour diagnosis—a realistic appraisal | |
| Papakosta et al. | Deciphering Atypical Signals Present in Fluorescent In Situ Hybridization Assays in the Diagnosis of Soft Tissue Sarcomas | |
| US20070009927A1 (en) | Methods and compositions for prenatal diagnosis of mental retardation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Transfer of assignment of patent |
Owner name: HELSINGIN YLIOPISTO Free format text: HELSINGIN YLIOPISTO |
|
| PC | Transfer of assignment of patent |
Owner name: DERMAGENE OY Free format text: DERMAGENE OY |
|
| PC | Transfer of assignment of patent |
Owner name: HELSINGIN YLIOPISTON RAHASTOT Free format text: HELSINGIN YLIOPISTON RAHASTOT |
|
| PC | Transfer of assignment of patent |
Owner name: VALIPHARMA |
|
| MM | Patent lapsed |